Application Of Two-dimensional Light Scattering Cytometry For Leukemia Cells Recognition

Leukemia is a malignant tumor with high morbidity and high mortality worldwide,which ranks first in the list of malignant tumors for children and adolescents.Leukemia has an increasing trend of morbidity and mortality in recent years.According to clinical experience,early diagnosis and targeted combination therapy are critical for improving the therapeutic effect of leukemia.Currently,the clinical diagnosis of leukemia is performed mainly according to the hemogram and bone marrow biopsy that is depending on the biochemical staining and immunohistochemical method to enable subtype determination.However,these methods are limited by its professionalism,complexity and high cost.Therefore,it is of great clinical significance and value to develop a new method for label-free diagnosis of leukemia.2D light scattering is an ideal label-free technique for early diagnosis of leukemia,which is fast,accurate,easy-to-use,non-contact and non-destructive.This work explores the feasibility and potential value of 2D light scattering for label-free early diagnosis of leukemia.Firstly,the basic contents of leukemia and light scattering are introduced and followed by the overview of hotspots and the latest trends in this field.Then the developed 2D light scattering static cytometry is introduced and its performance is tested to demonstrate the platform for early diagnosis of leukemia.Next,wide-angle 2D light scattering flow cytometry is developed,which has the capability to collect more information and achieve high-throughput detection.Finally,the application of the wide-angle 2D light scattering flow cytometry for label-free early diagnosis of leukemia is performed,realizing the automatic recognition and classification of acute lymphocytic leukemia cells Jurkat and chronic lymphocytic leukemia cells BALL-1·To summarize,the results of this study show that wide-angle 2D light scattering flow cytometry expects to be used for lymphoid leukemia cells identification with the advantages of high efficiency and label-free analysis.We suggest that the development platform may provide a new approach for the clinical diagnosis of leukemia.